Skip to content
Yog Pharma

Glipizide is a sulfonylurea indicated for type 2 diabetes mellitus. We supply it to US manufacturers of tablets and extended-release tablets.

CAS29094-61-9445.5 g/molC21H27N5O4S
2D structure of Glipizide.

Data from PubChem (CID 3478) and FDA’s substance registry

CAS number

29094-61-9

Molecular formula

C21H27N5O4S

Molecular weight

445.5g/mol

FDA UNII

IUPAC name

N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide

InChIKey

ZJJXGWJIGJFDTL-UHFFFAOYSA-N

Appearance
White or almost white, odorless crystalline powder.
Solubility
Insoluble in water and alcohols. Soluble in 0.1 N sodium hydroxide and freely soluble in dimethylformamide.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Insoluble in water, so dissolution is sensitive to particle size. State the range you developed with.

On the US market

Reference product
GlucotrolNDA 017783
Approved ANDAs
12 with a marketed product
Approved forms and strengths
  • Tablet 2.5 mg, 5 mg, 10 mg, 15 mg
  • Extended-release tablet 2.5 mg, 5 mg, 10 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com